Background Atrial fibrillation (AF) is a common cardiac arrhythmia that increases the risk of
stroke. Medical therapy for decreasing stroke risk involves anticoagulation, which may …

Risk factors for stroke and thromboembolism in patients with atrial fibrillation used in current
risk stratification schema are derived largely from analyses of clinical trial cohorts, and the …

Background Contemporary clinical risk stratification schemata for predicting stroke and
thromboembolism (TE) in patients with atrial fibrillation (AF) are largely derived from risk …

Background and Purpose—The risk of stroke in patients with atrial fibrillation (AF) is not
homogeneous, and various clinical risk factors have informed the development of stroke risk …

Background: Previous studies report that CHADS2 and CHA2DS2-VASc risk scores have
similar discriminating ability (C statistic∼ 0.6). Recently a clinically based risk score, the …

Background: Anticoagulation management of patients with atrial fibrillation (AF) should be
tailored individually on the basis of ischemic stroke risk. The objective of this study was to …

Summary Background The Apixaban for Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation (ARISTOTLE) trial showed that apixaban is better than warfarin at …

Objectives: We sought to evaluate the rate of bleeding in relation to age (< 80 and≥ 80
years), the quality of anticoagulation (expressed as time spent in international normalized …

The management of patients with supra-therapeutic INR in a common clinical problem. The
risk of bleeding is influenced by the intensity, variability and duration of anticoagulation …

The efficacy of adjusted-dose oral anticoagulant treatment (OAT) in the prevention of stroke
in atrial fibrillation (AF) is well documented. Available data show that AF patients are widely …